A detailed history of Bio Impact Capital LLC transactions in Regenxbio Inc. stock. As of the latest transaction made, Bio Impact Capital LLC holds 50,000 shares of RGNX stock, worth $479,500. This represents 0.08% of its overall portfolio holdings.

Number of Shares
50,000
Previous 557,076 91.02%
Holding current value
$479,500
Previous $6.52 Million 91.96%
% of portfolio
0.08%
Previous 1.05%

Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

SELL
$10.49 - $14.39 $5.32 Million - $7.3 Million
-507,076 Reduced 91.02%
50,000 $524,000
Q2 2024

Aug 14, 2024

BUY
$11.51 - $21.53 $92,056 - $172,196
7,998 Added 1.46%
557,076 $6.52 Million
Q4 2023

Feb 13, 2024

SELL
$12.89 - $20.82 $1.39 Million - $2.24 Million
-107,640 Reduced 16.39%
549,078 $9.86 Million
Q2 2023

Aug 14, 2023

BUY
$17.23 - $21.71 $672,779 - $847,710
39,047 Added 6.32%
656,718 $13.1 Million
Q1 2023

May 12, 2023

SELL
$18.08 - $24.55 $66,914 - $90,859
-3,701 Reduced 0.6%
617,671 $11.7 Million
Q4 2022

Feb 14, 2023

BUY
$20.4 - $24.73 $46,695 - $56,606
2,289 Added 0.37%
621,372 $14.1 Million
Q3 2022

Nov 14, 2022

BUY
$22.29 - $35.04 $13.8 Million - $21.7 Million
619,083 New
619,083 $16.4 Million

Others Institutions Holding RGNX

About REGENXBIO Inc.


  • Ticker RGNX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,230,000
  • Market Cap $415M
  • Description
  • REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprie...
More about RGNX
Track This Portfolio

Track Bio Impact Capital LLC Portfolio

Follow Bio Impact Capital LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bio Impact Capital LLC, based on Form 13F filings with the SEC.

News

Stay updated on Bio Impact Capital LLC with notifications on news.